Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high-lipid-containing tissues.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Clin. Endocrinol. Metab.

Title: The Journal of clinical endocrinology and metabolism

ISSN (Electronic): 1945-7197

ISSN (Print): 0021-972X

Publication date (Electronic): Aug 2015

Volume: 100

Issue: 8

Affiliations

[1 ] Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche (INSERM UMR)-S 1185 (S.H., J.Y., E.B., M.L.), Le Kremlin-Bicêtre F-94276, France; Department of Nuclear Medicine and Endocrine Oncology (S.H., E.B.) and Department of Pharmacology (A.S., F.C., S.B., A.P., E.B.), Gustave Roussy, Villejuif F-94805, France; INSERM UMR-S Institute of Cardiometabolism and Nutrition/1166, (M.G., T.H.) Pitié-Salpetrière Hospital, Paris, F-75013, France; Department of Endocrinology (J.Y., M.L.), Centre Hospitalier Universitaire Bicêtre, Le Kremlin-Bicêtre F-94276, France.

Article

DOI: 10.1210/JC.2015-2080

PubMed ID: 26120791

SO-VID: f4573d21-a345-417d-8dcd-e7fa1fc45c1d

History

Data availability:

Comments

Comment on this article

scite_

Cited by 11

See all cited by